Compare Franco-Nevada Corporation (FNV) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franco-Nevada Corporation vs Zoetis Inc — how do they compare? Franco-Nevada Corporation trades at $233.84 (market cap $46.80B), while Zoetis Inc trades at $75.31 (market cap $30.70B). The key difference: Franco-Nevada Corporation is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.85%). Which is the better fit depends on your goals — on Pluang, investors hold Franco-Nevada Corporation for 0 Days and Zoetis Inc for 71 Days on average.
| FNV | ZTS | |
|---|---|---|
Market Cap | $46.80B | $30.70B |
Volume | 310,692 | 3,299,421 |
Sector | Basic Materials | Health |
52-Week High | $280.82 | $147.53 |
52-Week Low | $183.97 | $69.09 |
Typical Hold Time | 0 Days | 71 Days |
Enterprise Value | $45.79B | $38.27B |
Dividend Yield | 0.72% | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Franco-Nevada (FNV) trades at $243.85, showing a slight decline of 0.77% over the past day. The stock is positioned neutrally from a technical perspective, with key support near $242 and resistance at $246. Fundamentally, the company exhibits strong profitability with a net income margin of 63.79% and has beaten earnings expectations in two of the last three quarters. Recent news highlights portfolio expansion, including a significant investment in the Bullabulling Gold Project and positive developments regarding the potential restart of the Cobre Panama mine.
The outlook for FNV is supported by analyst consensus, with a price target of $275 suggesting potential upside. Key opportunities include revenue growth from new projects and high profit margins. Risks involve execution on new investments, commodity price volatility, and geopolitical factors affecting mining operations. The balanced analyst rating split indicates cautious optimism for future performance.
Zoetis (ZTS) trades at $75.335, down 0.42% on the day, with a bullish technical signal from moving averages and ADX indicators. The company reported strong profitability with a 27.69% net income margin and 64.91% ROE for 2025, though Q1 2026 EPS missed expectations. Recent news highlights near-term headwinds in U.S. companion animal sales but underscores long-term resilience and industry-leading margins.
The outlook is cautiously optimistic, with a consensus price target of $87.33 implying 16% upside. Investment opportunities lie in Zoetis's robust fundamentals and market dominance, while risks include competitive pressures, weaker U.S. demand, and margin compression from promotions. The stock offers value at a P/E of 12.12, but investors should monitor Q3 2026 results for growth confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Franco-Nevada Corporation
Franco-Nevada Corporation is a royalty and streaming company that finances mining and energy projects in exchange for royalty payments or the right to purchase output at set prices, holding a diversified portfolio across Precious Metals, Other Mining, and Energy (oil, gas, and natural gas liquids).
Read more on FNV →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
